VIRI Insider Trading (Virios Therapeutics)
Insider Ownership Percentage: 18.60%
Insider Buying (Last 12 Months): $236,881.28
Insider Selling (Last 12 Months): $0.00
Virios Therapeutics Share Price & Price History
Current Price: $4.23
Price Change: ▲ Price Increase of +0.05 (1.20%)
As of 06/30/2022 01:00 AM ET
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Virios Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2022 | Angela Walsh | SVP | Buy | 2,000 | $4.58 | $9,160.00 | 3,000 |  |
| 5/23/2022 | Gregory Scott Duncan | CEO | Buy | 7,500 | $4.52 | $33,900.00 | 32,461 | |
| 5/17/2022 | William Pridgen | Director | Buy | 13,450 | $4.38 | $58,911.00 | 36,469 | |
| 3/29/2022 | William Pridgen | Director | Buy | 600 | $4.94 | $2,964.00 | | |
| 3/23/2022 | William Pridgen | Director | Buy | 2,197 | $5.46 | $11,995.62 | | |
| 1/27/2022 | William Pridgen | Director | Buy | 4,180 | $5.98 | $24,996.40 | | |
| 1/6/2022 | Richard James Whitley | Director | Buy | 1,800 | $5.72 | $10,296.00 | | |
| 12/23/2021 | Richard James Whitley | Director | Buy | 200 | $5.72 | $1,144.00 | | |
| 12/21/2021 | Gregory Scott Duncan | CEO | Buy | 5,000 | $5.52 | $27,600.00 | | |
| 12/21/2021 | William Pridgen | Director | Buy | 8,827 | $5.66 | $49,960.82 | | |
| 7/7/2021 | William Pridgen | Director | Buy | 942 | $6.32 | $5,953.44 | | |
| 4/5/2021 | Gregory Scott Duncan | CEO | Buy | 15,675 | $6.17 | $96,714.75 | 19,579 | |
| 1/29/2021 | William Pridgen | Director | Buy | 3,500 | $7.47 | $26,145.00 | 727,993 | |
| 1/28/2021 | Angela Walsh | VP | Buy | 1,000 | $7.30 | $7,300.00 | | |
| 12/17/2020 | William Pridgen | Director | Buy | 1,500 | $11.98 | $17,970.00 | 727,192 | |
Make Sure Your Alarm Is Set…
From Base Camp Trading | Ad
This early morning trade is constantly overlooked, but those who use it are retiring early!
Hi, I’m trading expert Dave Aquino and with my new guide, “How To Master The Retirement Trade”, you could be taking advantage of it as well!
The trade starts at 9:30EST…don’t be late!
Get a copy here!
>>>
Virios Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/16/2022 | UBS Group AG | 14,137 | $63K | 0.0% | +528.3% | 0.170% |  |
| 5/13/2022 | Vanguard Group Inc. | 241,666 | $1.08M | 0.0% | +63.4% | 2.901% | |
| 5/12/2022 | Cetera Advisors LLC | 43,944 | $0.20M | 0.0% | +22.0% | 0.528% | |
| 11/16/2021 | Captrust Financial Advisors | 40,145 | $0.21M | 0.0% | N/A | 0.482% | |
| 11/16/2021 | Cetera Advisors LLC | 48,432 | $0.26M | 0.0% | +100.0% | 0.581% | |
| 11/16/2021 | Masters Capital Management LLC | 650,000 | $3.44M | 0.1% | +8.3% | 7.803% | |
| 11/9/2021 | BlackRock Inc. | 15,856 | $84K | 0.0% | +64.3% | 0.190% | |
| 9/17/2021 | Virtu Financial LLC | 13,110 | $82K | 0.0% | N/A | 0.157% | |
| 8/13/2021 | Geode Capital Management LLC | 18,499 | $0.12M | 0.0% | N/A | 0.222% | |
| 8/13/2021 | Vanguard Group Inc. | 141,011 | $0.89M | 0.0% | N/A | 1.693% | |
| 5/18/2021 | Millennium Management LLC | 22,858 | $0.13M | 0.0% | +10.4% | 0.274% | |
| 5/17/2021 | Masters Capital Management LLC | 600,000 | $3.44M | 0.1% | +33.9% | 7.203% | |
| 5/14/2021 | PVG Asset Management Corp | 55,160 | $0.32M | 1.0% | N/A | 0.662% | |
| 5/4/2021 | Envestnet Asset Management Inc. | 27,844 | $0.16M | 0.0% | N/A | 0.334% | |
| 2/24/2021 | Virtu Financial LLC | 35,219 | $0.26M | 0.0% | N/A | 0.450% | |
| 2/17/2021 | Jane Street Group LLC | 95,230 | $0.72M | 0.0% | N/A | 1.216% | |
Data available starting January 2016
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Read More on Virios Therapeutics
Volume
2,391 shs
Average Volume
19,578 shs
Market Capitalization
$35.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Virios Therapeutics?
